Thomas Fischer

1.3k total citations
33 papers, 931 citations indexed

About

Thomas Fischer is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Thomas Fischer has authored 33 papers receiving a total of 931 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 13 papers in Oncology and 10 papers in Hematology. Recurrent topics in Thomas Fischer's work include Chronic Myeloid Leukemia Treatments (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Eosinophilic Disorders and Syndromes (4 papers). Thomas Fischer is often cited by papers focused on Chronic Myeloid Leukemia Treatments (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Eosinophilic Disorders and Syndromes (4 papers). Thomas Fischer collaborates with scholars based in Germany, United States and Switzerland. Thomas Fischer's co-authors include Stefan Jacobs, Stefan Schulz, Ralf Stumm, Andrej Banič, Angela Kolodziej, Christian Doll, Daniel J. DeAngelo, Andrew Spencer, Oliver G. Ottmann and Kapil N. Bhalla and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Thomas Fischer

33 papers receiving 912 citations

Peers

Thomas Fischer
Walid Zaher Saudi Arabia
Daniel W. Fort United States
Martin G. Sauer Germany
Rongfu Zhou China
Barbara Ziegler Austria
Wenhao Zhang China
Andreas Poschenrieder Germany
Judy Zhu United States
Susanne Oertel Germany
Julie A. Oliver United States
Walid Zaher Saudi Arabia
Thomas Fischer
Citations per year, relative to Thomas Fischer Thomas Fischer (= 1×) peers Walid Zaher

Countries citing papers authored by Thomas Fischer

Since Specialization
Citations

This map shows the geographic impact of Thomas Fischer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Fischer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Fischer more than expected).

Fields of papers citing papers by Thomas Fischer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Fischer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Fischer. The network helps show where Thomas Fischer may publish in the future.

Co-authorship network of co-authors of Thomas Fischer

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Fischer. A scholar is included among the top collaborators of Thomas Fischer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Fischer. Thomas Fischer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lüftner, Diana, Florian Schuetz, Andreas Schneeweiß, et al.. (2024). Efficacy and safety of everolimus plus exemestane in patients with hormone receptor‐positive, HER‐2‐negative advanced breast cancer: Results from the open‐label, multicentre, non‐interventional BRAWO study. International Journal of Cancer. 155(1). 128–138. 1 indexed citations
2.
Sauerwein, W., Thomas Fischer, Lucie Sancey, et al.. (2023). Principles, Recent Developmentsand Perspectives in Boron NeutronCapture Therapy (BNCT). Bio-Algorithms and Med-Systems. 19(1). 48–53. 3 indexed citations
3.
Fischer, Thomas, Oliver Hartmann, Cristian Prieto‐Garcia, et al.. (2022). PTEN mutant non-small cell lung cancer require ATM to suppress pro-apoptotic signalling and evade radiotherapy. Cell & Bioscience. 12(1). 50–50. 16 indexed citations
4.
Prieto‐Garcia, Cristian, Oliver Hartmann, Thomas Fischer, et al.. (2021). Inhibition of USP28 overcomes Cisplatin-resistance of squamous tumors by suppression of the Fanconi anemia pathway. Cell Death and Differentiation. 29(3). 568–584. 24 indexed citations
5.
6.
Hartmann, Oliver, Thomas Fischer, Cristian Prieto‐Garcia, et al.. (2021). Implementation of CRISPR/Cas9 Genome Editing to Generate Murine Lung Cancer Models That Depict the Mutational Landscape of Human Disease. Frontiers in Cell and Developmental Biology. 9. 641618–641618. 20 indexed citations
7.
Prieto‐Garcia, Cristian, Oliver Hartmann, Fabian Braun, et al.. (2020). Maintaining protein stability of ∆Np63 via USP 28 is required by squamous cancer cells. EMBO Molecular Medicine. 12(4). e11101–e11101. 43 indexed citations
8.
Polat, Bülent, Gisela Wohlleben, Thomas Gehrke, et al.. (2017). Perioperative changes in osteopontin and TGFβ1 plasma levels and their prognostic impact for radiotherapy in head and neck cancer. BMC Cancer. 17(1). 6–6. 5 indexed citations
9.
DeAngelo, Daniel J., Andrew Spencer, Kapil N. Bhalla, et al.. (2013). Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia. 27(8). 1628–1636. 116 indexed citations
10.
Jahnke, Kristoph, Agnieszka Korfel, Peter Martus, et al.. (2011). Prognostic factors for response and survival in primary central nervous system lymphoma (PCNSL) from a randomized phase III trial (G-PCNSL-SG-1).. Journal of Clinical Oncology. 29(15_suppl). 2004–2004. 2 indexed citations
11.
Fischer, Thomas, Christian Doll, Stefan Jacobs, et al.. (2008). Reassessment of sst2Somatostatin Receptor Expression in Human Normal and Neoplastic Tissues Using the Novel Rabbit Monoclonal Antibody UMB-1. The Journal of Clinical Endocrinology & Metabolism. 93(11). 4519–4524. 109 indexed citations
12.
Fischer, Thomas, Falko Nagel, Stefan Jacobs, Ralf Stumm, & Stefan Schulz. (2008). Reassessment of CXCR4 Chemokine Receptor Expression in Human Normal and Neoplastic Tissues Using the Novel Rabbit Monoclonal Antibody UMB-2. PLoS ONE. 3(12). e4069–e4069. 58 indexed citations
13.
Deininger, Michael W., Jörge E. Cortes, Ron Paquette, et al.. (2007). The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome‐negative cells. Cancer. 110(7). 1509–1519. 74 indexed citations
14.
Ramı́rez, Tzutzuy, Helga Stopper, Thomas Fischer, Robert Hock, & Luis A. Herrera. (2007). S-Adenosyl-l-methionine counteracts mitotic disturbances and cytostatic effects induced by sodium arsenite in HeLa cells. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 637(1-2). 152–160. 11 indexed citations
15.
Schuchmann, Marcus, Henning Schulze‐Bergkamen, Jörn M. Schattenberg, et al.. (2006). Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncology Reports. 15(1). 227–30. 63 indexed citations
16.
Banič, Andrej, et al.. (2006). Evaluation of Late Results in Breast Reconstruction by Latissimus Dorsi Flap and Prosthesis Implantation. Plastic & Reconstructive Surgery. 117(5). 1387–1394. 73 indexed citations
17.
18.
Roesel, Johannes, Guido Bold, Josef Brueggen, et al.. (2005). Pharmacological profile of the FLT3-Tyrosine Kinase Inhibitor AST487. Cancer Research. 65. 1409–1409. 1 indexed citations
19.
Schmitz, Norbert, Per Ljungman, Charlotte Cordonnier, et al.. (2004). Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial. Bone Marrow Transplantation. 34(11). 955–962. 40 indexed citations
20.
Fischer, Thomas, M.K. Miller, Corinne Bott‐Silverman, & Alan Lichtin. (1996). POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE AFTER CARDIAC TRANSPLANTATION. Transplantation. 62(11). 1687–1690. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Walid Zaher Breakdown of academic impact, for papers by Daniel W. Fort Breakdown of academic impact, for papers by Martin G. Sauer Breakdown of academic impact, for papers by Rongfu Zhou Breakdown of academic impact, for papers by Barbara Ziegler Breakdown of academic impact, for papers by Wenhao Zhang Breakdown of academic impact, for papers by Andreas Poschenrieder Breakdown of academic impact, for papers by Judy Zhu Breakdown of academic impact, for papers by Susanne Oertel Breakdown of academic impact, for papers by Julie A. Oliver
Rankless by CCL
2026